In January 2025, several companies announced collaborations with international pharmaceutical giants to launch a series of new drugs globally.

In January 2025, a series of collaborative agreements were successively reached in the field of antibody-based pharmaceuticals in China.

In January 2025, China’s innovative pharmaceutical sector continues to make its mark on the global stage.

In January 2025, several significant mergers and acquisitions (M&A) took place in the biopharmaceutical industry.

10.28-11.3, Global Pharmaceutical Investment, Financing and Deal Events Summary.

Summary of Global Pharmaceutical Licensing Agreements and Financing Events from September 16 to September 22.

This week, multinational pharmaceutical companies including Sanofi, Bayer, Gilead Sciences, Novo Nordisk, and Pfizer have been notably active.

This article will use Pfizer as an example to teach you how to quickly learn to read Pharma/Biotech financial reports.

Pathios Therapeutics Secures $25M in Series B Funding for Cancer Drug Development.

Medincell and AbbVie Partner to Co-Develop Six Long-Acting Injectables.

On April 10, 2024, Vertex Pharmaceuticals ("Vertex") and Alpine Immune Sciences ("Alpine") announced that the parties entered into a definitive agreement. the parties have entered into a definitive agreement.

On April 12, 2024, Arvinas announced that it has entered into an exclusive strategic license agreement with Novartis to collaborate on the development of Arvinas' second-generation androgen receptor (AR) degrader, ARV-766.